Erasca, Inc. (ERAS): Price and Financial Metrics
ERAS Price/Volume Stats
| Current price | $1.44 | 52-week high | $3.45 |
| Prev. close | $1.38 | 52-week low | $1.01 |
| Day low | $1.37 | Volume | 864,429 |
| Day high | $1.55 | Avg. volume | 1,589,242 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $2.35 | Market Cap | 407.90M |
ERAS Stock Price Chart Interactive Chart >
Erasca, Inc. (ERAS) Company Bio
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
ERAS Price Returns
| 1-mo | -3.36% |
| 3-mo | -27.64% |
| 6-mo | -45.45% |
| 1-year | -25.39% |
| 3-year | -82.22% |
| 5-year | N/A |
| YTD | -42.63% |
| 2024 | 17.84% |
| 2023 | -50.58% |
| 2022 | -72.34% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...